Tahlita C. M. Zuiverloon, MD, PhD

Articles by Tahlita C. M. Zuiverloon, MD, PhD

Clinical Decision Making in Surveillance of Non–Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers

ByTahlita C. M. Zuiverloon, MD, PhD,Florus C. de Jong, MD,Dan Theodorescu, MD, PhD

December 15th 2017

In this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation. We also review current surveillance guidelines for NMIBC and provide an overview of approved urine markers for the detection and surveillance of NMIBC.

Latest Updated Articles

Clinical Decision Making in Surveillance of Non–Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers
December 15th 2017

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)